|The following article features coverage from the 2020 Genitourinary Cancers Symposium meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
SAN FRANCISCO—Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) may benefit from earlier use of cabazitaxel, according to study findings presented at the 2020 Genitourinary Cancers Symposium.
In a multicenter phase 2 trial, a team led by Susan F. Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York, randomly assigned 81 men with mCRPC (median age 68 years) to receive a combination of abiraterone acetate plus prednisone (AAP) and cabazitaxel (39 patients) or AAP alone (42 patients) with crossover to cabazitaxel upon AAP failure. None of the patients previously had received chemotherapy. The primary endpoint was radiographic progression-free survival (rPFS), defined as the time from randomization to radiographic progression or death, which occurred first.
Compared with the monotherapy arm, the combination arm had a longer median time to rPFS 14.4 vs 7.9 months) and PSA progression (13.8 vs 9 months), Dr Slovin and her colleagues reported in a poster presentation. Median overall survival time was 20.7 months in the combination arm and 16.4 months in the monotherapy arm. The proportion of patients who experienced a 50% of greater decline in PSA from baseline was 87.2% in the combination arm and 52.4% in the monotherapy arm. The treatments were well tolerated, according to the investigators.
Trial results support further study of the combination of AAP and cabazitaxel in men with mCRPC, the authors concluded.
Disclosure: Research funding from Sanofi US Services, Inc.
Read more of our coverage of the 2020 Genitourinary Cancers Symposium by visiting the conference page.
Slovin SF, Knudsen KE, Halabi S, et al. Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC). Presented at the 2020 Genitourinary Cancers Symposium held February 13 to 15 in San Francisco. Abstract 84.
This article originally appeared on Renal and Urology News